Vaccines against Toxoplasma gondii: status, challenges and future directions
- PMID: 22906945
- PMCID: PMC3579912
- DOI: 10.4161/hv.21006
Vaccines against Toxoplasma gondii: status, challenges and future directions
Abstract
Toxoplasma gondii is a ubiquitous protozoan parasite that can infect a wide range of animals including humans. This single known species in the genus Toxoplasma is considered as one of the most successful eukaryotic pathogens which is of major medical and veterinary importance. Effective vaccines may contribute toward preventing and controlling the spread of toxoplasmosis. The present communication addresses the current status of development of vaccines against T. gondii. Further discussion is made on the difficulties along with challenges, such as vaccine construct, mode of vaccine administration and standardization of immunization evaluation. Finally suggestions are made on possible directions for future research on the development of vaccines against T. gondii.
Similar articles
-
Immunization with a DNA vaccine encoding Toxoplasma gondii Superoxide dismutase (TgSOD) induces partial immune protection against acute toxoplasmosis in BALB/c mice.BMC Infect Dis. 2017 Jun 7;17(1):403. doi: 10.1186/s12879-017-2507-5. BMC Infect Dis. 2017. PMID: 28592247 Free PMC article.
-
IL-17 and IL-22 elicited by a DNA vaccine encoding ROP13 associated with protection against Toxoplasma gondii in BALB/c mice.J Cell Physiol. 2019 Jul;234(7):10782-10788. doi: 10.1002/jcp.27747. Epub 2018 Nov 22. J Cell Physiol. 2019. PMID: 30565688
-
Toxoplasma gondii: Vaccination with a DNA vaccine encoding T- and B-cell epitopes of SAG1, GRA2, GRA7 and ROP16 elicits protection against acute toxoplasmosis in mice.Vaccine. 2015 Nov 27;33(48):6757-62. doi: 10.1016/j.vaccine.2015.10.077. Epub 2015 Oct 27. Vaccine. 2015. PMID: 26518401
-
Advances in the Development of Anti-Toxoplasma gondii Vaccines: Challenges, Opportunities, and Perspectives.Trends Parasitol. 2019 Mar;35(3):239-253. doi: 10.1016/j.pt.2019.01.005. Epub 2019 Feb 1. Trends Parasitol. 2019. PMID: 30718083 Review.
-
Vaccination challenges and strategies against long-lived Toxoplasma gondii.Vaccine. 2019 Jul 9;37(30):3989-4000. doi: 10.1016/j.vaccine.2019.05.083. Epub 2019 Jun 8. Vaccine. 2019. PMID: 31186188 Review.
Cited by
-
AMA1-deficient Toxoplasma gondii parasites transiently colonize mice and trigger an innate immune response that leads to long-lasting protective immunity.Infect Immun. 2015 Jun;83(6):2475-86. doi: 10.1128/IAI.02606-14. Epub 2015 Apr 6. Infect Immun. 2015. PMID: 25847964 Free PMC article.
-
The Search for Drugs Derived from Natural Products for Toxoplasma gondii Infection Treatment in the Last 20 Years - A Systematic Review.Curr Top Med Chem. 2024;24(22):1960-1999. doi: 10.2174/0115680266299409240606062235. Curr Top Med Chem. 2024. PMID: 38952156
-
REVIEW OF DNA VACCINE APPROACHES AGAINST THE PARASITE TOXOPLASMA GONDII.J Parasitol. 2021 Nov 1;107(6):882-903. doi: 10.1645/20-157. J Parasitol. 2021. PMID: 34852176 Free PMC article. Review.
-
Cross-sectional association of Toxoplasma gondii exposure with BMI and diet in US adults.PLoS Negl Trop Dis. 2021 Oct 1;15(10):e0009825. doi: 10.1371/journal.pntd.0009825. eCollection 2021 Oct. PLoS Negl Trop Dis. 2021. PMID: 34597323 Free PMC article.
-
Heterologous immunization targeting the CST1 antigen confers better protection than ROP18 in mice.Nanomedicine (Lond). 2024;19(29):2437-2446. doi: 10.1080/17435889.2024.2403333. Epub 2024 Sep 25. Nanomedicine (Lond). 2024. PMID: 39320318
References
-
- Serranti D, Buonsenso D, Valentini P. [Congenital toxoplasmosis treatment] Eur Rev Med Pharmacol Sci. 2011;15:193–8. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources